Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215-19. doi: 10.1128/AAC.01215-19. [Epub ahead of print] Review.

PMID:
31591118
2.

Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.

Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, Gonzalez Garcia J, Peloquin CA, Blaschke T, Vaida F, Benson CA.

PLoS Med. 2019 Oct 4;16(10):e1002891. doi: 10.1371/journal.pmed.1002891. eCollection 2019 Oct.

3.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
4.

Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.

Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT, Ganatra S, Tornheim JA, Chawla P, Caoili JC, Ritchie B, Jain SK, Dartois V, Dooley KE.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00913-19. doi: 10.1128/AAC.00913-19. Print 2019 Oct.

PMID:
31383662
5.

Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.

Enimil A, Antwi S, Yang H, Dompreh A, Alghamdi WA, Gillani FS, Orstin A, Bosomtwe D, Opoku T, Norman J, Wiesner L, Langaee T, Peloquin CA, Court MH, Greenblatt DJ, Kwara A.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00839-19. doi: 10.1128/AAC.00839-19. Print 2019 Oct.

PMID:
31332062
6.

Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.

Al-Shaer MH, Alghamdi WA, Graham E, Peloquin CA.

Ther Drug Monit. 2019 Jul 15. doi: 10.1097/FTD.0000000000000675. [Epub ahead of print]

PMID:
31318843
7.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
8.

Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.

Alghamdi WA, Antwi S, Enimil A, Yang H, Dompreh A, Wiesner L, Langaee T, Peloquin CA, Kwara A.

J Antimicrob Chemother. 2019 Sep 1;74(9):2698-2706. doi: 10.1093/jac/dkz238.

PMID:
31243456
9.

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Cegielski JP, Kempker RR, Heysell SK, Peloquin CA.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00279-19. doi: 10.1128/AAC.00279-19. Print 2019 Jul.

10.

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Alghamdi WA, Alsultan A, Al-Shaer MH, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Schmidt S, Heysell SK, Kempker RR, Cegielski JP, Peloquin CA.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00055-19. doi: 10.1128/AAC.00055-19. Print 2019 May.

11.

Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.

Malik AA, Brooks MB, Siddiqui S, Fuad J, Peloquin CA, Amanullah F, Jaswal M, Becerra MC, Hussain H, Yuen CM.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02569-18. doi: 10.1128/AAC.02569-18. Print 2019 May.

PMID:
30803975
12.

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2019 May 1;199(9):1167-1168. doi: 10.1164/rccm.201812-2281LE. No abstract available.

13.

Bacterial Factors and Relapse after Tuberculosis Therapy.

Alsultan A, Ashkin D, Peloquin CA.

N Engl J Med. 2019 Jan 10;380(2):197. doi: 10.1056/NEJMc1813645. No abstract available.

PMID:
30628424
14.

Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

Tucker EW, Guglieri-Lopez B, Ordonez AA, Ritchie B, Klunk MH, Sharma R, Chang YS, Sanchez-Bautista J, Frey S, Lodge MA, Rowe SP, Holt DP, Gobburu JVS, Peloquin CA, Mathews WB, Dannals RF, Pardo CA, Kannan S, Ivaturi VD, Jain SK.

Sci Transl Med. 2018 Dec 5;10(470). pii: eaau0965. doi: 10.1126/scitranslmed.aau0965.

PMID:
30518610
15.

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01657-18. doi: 10.1128/AAC.01657-18. Print 2019 Jan.

16.

Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Justine M, Yeconia A, Nicodemu I, Augustino D, Gratz J, Mduma E, Heysell SK, Kivuyo S, Mfinanga S, Peloquin CA, Zagurski T, Kibiki GS, Mmbaga B, Houpt ER, Thomas TA.

J Pediatric Infect Dis Soc. 2018 Nov 5. doi: 10.1093/jpids/piy106. [Epub ahead of print]

PMID:
30395239
17.

Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.

Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H.

Int J Antimicrob Agents. 2019 Mar;53(3):275-283. doi: 10.1016/j.ijantimicag.2018.10.012. Epub 2018 Oct 29.

PMID:
30385322
18.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

19.

Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.

Venugopalan V, Manigaba K, Borgert SJ, Cope J, Peloquin CA, Klinker KP.

Microbiol Insights. 2018 Oct 14;11:1178636118804549. doi: 10.1177/1178636118804549. eCollection 2018.

20.

A PRELIMINARY ANALYSIS OF PROLONGED ABSORPTION RATE OF PONAZURIL IN RED-FOOTED TORTOISES, CHELONOIDIS CARBONARIA.

Benge SL, Heinrichs MT, Crevasse SE, Mahjoub B, Peloquin CA, Wellehan JFX Jr.

J Zoo Wildl Med. 2018 Sep;49(3):802-805. doi: 10.1638/2017-0178.1.

PMID:
30212324
21.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

22.

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.

Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.

23.

Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Ortsin A, Dompreh A, Yang H, Wiesner L, Peloquin CA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00008-18. doi: 10.1128/AAC.00008-18. Print 2018 Sep.

24.

Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs.

Heinrichs MT, May RJ, Heider F, Reimers T, B Sy SK, Peloquin CA, Derendorf H.

Int J Mycobacteriol. 2018 Apr-Jun;7(2):156-161. doi: 10.4103/ijmy.ijmy_33_18.

25.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
26.

Protein Binding of First-Line Antituberculosis Drugs.

Alghamdi WA, Al-Shaer MH, Peloquin CA.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00641-18. doi: 10.1128/AAC.00641-18. Print 2018 Jul.

27.

Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.

Lyles G, Ogarkov O, Zhdanova S, Peloquin CA, Ebers A, Pfaeffle H, Al-Shaer MH, Moiseeva E, Zorkaltseva E, Koscheev M, Houpt ER, Heysell SK.

Eur Respir J. 2018 May 24;51(5). pii: 1800109. doi: 10.1183/13993003.00109-2018. Print 2018 May. No abstract available.

28.

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.

Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Peloquin CA, Johnson JL, Sizemore EE, Mac Kenzie WR.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01802-17. doi: 10.1128/AAC.01802-17. Print 2018 May.

29.

A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Little BP, Bernheim A, Derendorf H, Blumberg HM, Vashakidze S, Peloquin CA.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702166. doi: 10.1183/13993003.02166-2017. Print 2018 Feb. No abstract available.

30.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.

Alffenaar JWC, Peloquin CA, Migliori GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. No abstract available.

PMID:
29297417
31.

Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available.

32.

Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"

Peloquin CA, Kempker RR.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01937-17. doi: 10.1128/AAC.01937-17. Print 2018 Jan. No abstract available.

33.

Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.

Dompreh A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E, Antwi S, Enimil A, Langaee T, Peloquin CA, Court MH, Kwara A.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02099-17. doi: 10.1128/AAC.02099-17. Print 2018 Mar.

34.

Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.

Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Gogishvili S, Little BP, Bernheim A, Guarner J, Peloquin CA, Blumberg HM, Derendorf H, Kempker RR.

J Antimicrob Chemother. 2018 Feb 1;73(2):477-483. doi: 10.1093/jac/dkx421.

35.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

36.

Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.

Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01692-17. doi: 10.1128/AAC.01692-17. Print 2018 Jan.

37.

Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01524-17. doi: 10.1128/AAC.01524-17. Print 2017 Sep. No abstract available.

38.

Reply to Srivastava et al., "pH Conditions under Which Pyrazinamide Works in Humans".

Kempker RR, Peloquin CA, Blumberg HM, Vashakidze S.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01120-17. doi: 10.1128/AAC.01120-17. Print 2017 Sep. No abstract available.

39.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492
40.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

41.

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

42.

Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Yang H, Enimil A, Gillani FS, Antwi S, Dompreh A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A.

Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687.

43.

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

44.

Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt.

Harausz EP, Leigh J, Garcia-Prats AJ, Furin J, Peloquin CA.

Clin Infect Dis. 2017 Aug 15;65(4):704-705. doi: 10.1093/cid/cix434. No abstract available.

PMID:
28482036
45.

Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Tukvadze N, Little B, Bernheim A, Read TD, Guarner J, Derendorf H, Peloquin CA, Blumberg HM, Vashakidze S.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00226-17. doi: 10.1128/AAC.00226-17. Print 2017 Jun.

46.

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.

Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, Langaee TY, Peloquin CA, Johnson JA, Cavallari LH.

Pharmacogenet Genomics. 2017 May;27(5):190-196. doi: 10.1097/FPC.0000000000000277.

47.

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02625-16. doi: 10.1128/AAC.02625-16. Print 2017 Jun.

48.

Mycobacterium tuberculosis Infection among Asian Elephants in Captivity.

Simpson G, Zimmerman R, Shashkina E, Chen L, Richard M, Bradford CM, Dragoo GA, Saiers RL, Peloquin CA, Daley CL, Planet P, Narachenia A, Mathema B, Kreiswirth BN.

Emerg Infect Dis. 2017 Mar;23(3):513-516. doi: 10.3201/eid2303.160726. Erratum in: Emerg Infect Dis. 2017 Apr;23(4):724.

49.

Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.

Alsultan A, Peloquin CA.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):121-123. doi: 10.5588/ijtld.16.0689. No abstract available.

PMID:
28157477
50.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

Supplemental Content

Loading ...
Support Center